Last reviewed · How we verify
BL-7040
BL-7040 is a small molecule that acts as a sphingosine-1-phosphate receptor 1 (S1P1) modulator.
BL-7040 is a small molecule that acts as a sphingosine-1-phosphate receptor 1 (S1P1) modulator. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | BL-7040 |
|---|---|
| Sponsor | BioLineRx, Ltd. |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
By modulating the S1P1 receptor, BL-7040 aims to reduce inflammation and potentially treat autoimmune diseases. S1P1 is a key receptor involved in the regulation of immune cell trafficking and lymphocyte egress from lymphoid organs.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BL-7040 CI brief — competitive landscape report
- BL-7040 updates RSS · CI watch RSS
- BioLineRx, Ltd. portfolio CI